© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
April 14th 2021, 1:00pm
Reintroducing treatment with Jakafi in patients with myelofibrosis after previous discontinuation extended overall survival compared to those patients who stopped permanently, although there was a substantial rate of permanent treatment discontinuation with this therapy.
April 2nd 2021, 6:00pm
At four-year follow up, treatment with givinostat, a histone-deacetylase inhibitor, continued to be safe and effective with no serious or life-threatening side effects.
March 17th 2021, 9:00pm
Of note, estimates show that there are more than 25,000 patients undergoing allogeneic hematopoietic cell transplantations throughout the United States and beyond. Recent study results show that these patients may be at a higher risk for de novo atrial fibrillation.
December 18th 2020, 12:00am
Watch our Myeloproliferative Neoplasms Webinar where an expert panel discussed topics highly relevant to patients, caregivers and advocates right now.
December 6th 2020, 6:23pm
In an interview with CURE®, lead study investigator Dr. John Mascarenhas discusses what the results of the phase 2 IMbark study could mean for the future of patients with myelofibrosis.
December 5th 2020, 8:00pm
An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.
December 5th 2020, 3:00pm
Five patient advocates, two oncologists and one caregiver were honored during CURE®’s eighth annual MPN Heroes Program.
December 5th 2020, 12:00am
Watch the entire MPN Heroes program here!
November 19th 2020, 10:00pm
Patients with myeloproliferative neoplasm (MPN) may benefit from this combination treatment if they are in the accelerated or blast phase of the disease.
August 13th 2020, 3:00pm
In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Ruben Mesa about understanding a myeloproliferative neoplasm diagnosis.
Ayvakit Shows Promise for Patients with Gastrointestinal Stomach Tumors With Specific Mutation
FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer
Learning to be a Kinder Person After Cancer